These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 27198868)

  • 1. Pay drug companies $1bn for each new antibiotic, says report.
    Owen J
    BMJ; 2016 May; 353():i2863. PubMed ID: 27198868
    [No Abstract]   [Full Text] [Related]  

  • 2. Stimulating antibiotic development.
    Tillotson G
    Lancet Infect Dis; 2010 Jan; 10(1):2-3. PubMed ID: 20129141
    [No Abstract]   [Full Text] [Related]  

  • 3. Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals.
    Kesselheim AS; Outterson K
    Health Aff (Millwood); 2010 Sep; 29(9):1689-96. PubMed ID: 20820028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is the GAIN Act a turning point in new antibiotic discovery?
    Brown ED
    Can J Microbiol; 2013 Mar; 59(3):153-6. PubMed ID: 23540332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Report urges controversial 'delinkage' to foster new antibiotics.
    Holmes D
    Nat Med; 2014 Apr; 20(4):320. PubMed ID: 24710363
    [No Abstract]   [Full Text] [Related]  

  • 6. What are the economic barriers of antibiotic R&D and how can we overcome them?
    Renwick M; Mossialos E
    Expert Opin Drug Discov; 2018 Oct; 13(10):889-892. PubMed ID: 30175625
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug development: Time for teamwork.
    May M
    Nature; 2014 May; 509(7498):S4-5. PubMed ID: 24784427
    [No Abstract]   [Full Text] [Related]  

  • 8. The drug-resistant bacteria that pose the greatest health threats.
    Willyard C
    Nature; 2017 Feb; 543(7643):15. PubMed ID: 28252092
    [No Abstract]   [Full Text] [Related]  

  • 9. Novel Programs and Discoveries Aim to Combat Antibiotic Resistance.
    Hampton T
    JAMA; 2015 Jun 23-30; 313(24):2411-3. PubMed ID: 26039283
    [No Abstract]   [Full Text] [Related]  

  • 10. Implementation of a Market Entry Reward within the United States.
    Daniel GW; Schneider M; Lopez MH; McClellan MB
    J Law Med Ethics; 2018 Jun; 46(1_suppl):50-58. PubMed ID: 30146957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wild-card patent extensions as a means to incentivize research and development of antibiotics.
    Sonderholm J
    J Law Med Ethics; 2009; 37(2):240-6. PubMed ID: 19493069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving antibiotic markets for long-term sustainability.
    Kesselheim AS; Outterson K
    Yale J Health Policy Law Ethics; 2011; 11(1):101-67. PubMed ID: 21381513
    [No Abstract]   [Full Text] [Related]  

  • 13. Antibacterial R&D incentives.
    Laxminarayan R; Powers JH
    Nat Rev Drug Discov; 2011 Sep; 10(10):727-8. PubMed ID: 21959280
    [No Abstract]   [Full Text] [Related]  

  • 14. The critical impact of time discounting on economic incentives to overcome the antibiotic market failure.
    Spellberg B; Sharma P; Rex JH
    Nat Rev Drug Discov; 2012 Feb; 11(2):168. PubMed ID: 22293569
    [No Abstract]   [Full Text] [Related]  

  • 15. Incentives aim to boost antibiotic development.
    Roberts JP
    Nat Biotechnol; 2012 Aug; 30(8):735. PubMed ID: 22871701
    [No Abstract]   [Full Text] [Related]  

  • 16. The Economic Conundrum for Antibacterial Drugs.
    Shlaes DM
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31658969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Countries mull over incentives for developing antibiotics.
    Anderson T
    Lancet; 2016 May; 387(10031):1894-5. PubMed ID: 27203638
    [No Abstract]   [Full Text] [Related]  

  • 18. The economics of resistant pathogens and antibiotic innovation.
    McKellar MR; Chernew ME; Fendrick AM
    Am J Manag Care; 2014 Mar; 20(3):193-7. PubMed ID: 24884749
    [No Abstract]   [Full Text] [Related]  

  • 19. The drug push.
    Servick K
    Science; 2015 May; 348(6237):850-3. PubMed ID: 25999488
    [No Abstract]   [Full Text] [Related]  

  • 20. Lack of funding could undermine UK antibiotic resistance strategy, say experts.
    O'Dowd A
    BMJ; 2013 Dec; 347():f7618. PubMed ID: 24355390
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.